Trials / Completed
CompletedNCT01750216
An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR on Sustained Virological Response in Different Stages of Liver Fibrosis in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1
An Observational Study of Peginterferon-alfa-2a (Pegasys) and Ribavirin (Copegus) on Predictive Values of RVR on Sustained Virological Response (SVR) in Different Stage of Liver Fibrosis in Treatment-naïve Patients With Genotype 1 Chronic Hepatitis C
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 196 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This observational study will evaluate the predictive value of rapid virological response (RVR) and early virological response (EVR) on sustained virological response (SVR) by stage of liver fibrosis in treatment-naïve patients with chronic hepatitis C genotype 1 initiated on treatment with Pegasys (peginterferon alfa-2a) and Copegus (ribavirin). Patients will be followed for 48 weeks of treatment and up to 24 weeks of follow-up.
Conditions
Timeline
- Start date
- 2012-07-01
- Primary completion
- 2015-01-01
- Completion
- 2015-01-01
- First posted
- 2012-12-17
- Last updated
- 2016-11-02
Locations
14 sites across 1 country: Poland
Source: ClinicalTrials.gov record NCT01750216. Inclusion in this directory is not an endorsement.